Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kent W Mouw

Showing results (81-90 of 121) with videos related to

Pageof 13
Sort By:
International Journal of Radiation Oncology, Biology, Physics|January 6, 2024
The Next Chapter in Immunotherapy and Radiation Combination Therapy: Cancer-Specific PerspectivesAmy J Wisdom, Christopher A Barker, Joe Y Chang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 2021
<i>CDKN2A</i> Alterations and Response to Immunotherapy in Solid TumorsElio Adib, Amin H Nassar, Elie W Akl, et al.
International Journal of Radiation Oncology, Biology, Physics|May 8, 2014
Dosimetric consequences of interobserver variability in delineating the organs at risk in gynecologic interstitial brachytherapyAntonio L Damato, Kanopkis Townamchai, Michele Albert, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 19, 2025
CT online adaptive radiotherapy is associated with dosimetric and acute toxicity improvements in prostate cancer treatmentLin L Zhu, Jeremy S Bredfeldt, Yue-Houng Hu, et al.
Nature Communications|January 17, 2023
CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancerTakuya Tsujino, Tomoaki Takai, Kunihiko Hinohara, et al.
Scientific Reports|November 23, 2023
Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinomaAurel Prosz, Haohui Duan, Viktoria Tisza, et al.
Biorxiv : the Preprint Server for Biology|February 17, 2023
Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinomaAurel Prosz, Haohui Duan, Viktoria Tisza, et al.
Urologic Oncology|September 10, 2023
Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapyKendrick Yim, Kevin Melnick, Sarah L Mott, et al.
Medrxiv : the Preprint Server for Health Sciences|April 3, 2026
Clinical and genomic profiling of early-onset bladder cancer identifies key alterations and therapeutic targetsChristopher J Magnani, Vincent D D'Andrea, Guilherme Garcia Barros, et al.
Nature Cancer|February 5, 2022
Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncologyBrendan Reardon, Nathanael D Moore, Nicholas S Moore, et al.
Pageof 13

Showing results (81-90 of 121) with videos related to

Sort By:
Pageof 13
International Journal of Radiation Oncology, Biology, Physics|January 6, 2024
The Next Chapter in Immunotherapy and Radiation Combination Therapy: Cancer-Specific PerspectivesAmy J Wisdom, Christopher A Barker, Joe Y Chang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 2021
<i>CDKN2A</i> Alterations and Response to Immunotherapy in Solid TumorsElio Adib, Amin H Nassar, Elie W Akl, et al.
International Journal of Radiation Oncology, Biology, Physics|May 8, 2014
Dosimetric consequences of interobserver variability in delineating the organs at risk in gynecologic interstitial brachytherapyAntonio L Damato, Kanopkis Townamchai, Michele Albert, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 19, 2025
CT online adaptive radiotherapy is associated with dosimetric and acute toxicity improvements in prostate cancer treatmentLin L Zhu, Jeremy S Bredfeldt, Yue-Houng Hu, et al.
Nature Communications|January 17, 2023
CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancerTakuya Tsujino, Tomoaki Takai, Kunihiko Hinohara, et al.
Scientific Reports|November 23, 2023
Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinomaAurel Prosz, Haohui Duan, Viktoria Tisza, et al.
Biorxiv : the Preprint Server for Biology|February 17, 2023
Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinomaAurel Prosz, Haohui Duan, Viktoria Tisza, et al.
Urologic Oncology|September 10, 2023
Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapyKendrick Yim, Kevin Melnick, Sarah L Mott, et al.
Medrxiv : the Preprint Server for Health Sciences|April 3, 2026
Clinical and genomic profiling of early-onset bladder cancer identifies key alterations and therapeutic targetsChristopher J Magnani, Vincent D D'Andrea, Guilherme Garcia Barros, et al.
Nature Cancer|February 5, 2022
Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncologyBrendan Reardon, Nathanael D Moore, Nicholas S Moore, et al.
Pageof 13